A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update.

被引：0
|
作者：
van Oosterom, A
Reichardt, P
Blay, JY
Dumez, H
Fletcher, J
Debiec-Rychter, M
Shand, N
Drimitrijevic, S
Yap, A
Demetri, G
机构：
[1] UZ Gasthuisberg, Louvain, Belgium
[2] Charite, Berlin, Germany
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Novartis Pharm AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：824S / 824S
页数：1
相关论文
共 50 条
  • [31] Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study
    Raut, Chandrajit P.
    Espat, N. Joseph
    Maki, Robert G.
    Araujo, Dejka M.
    Williams, Toni Faith
    Wolff, Johannes E.
    DeMatteo, Ronald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Randomized phase 3 trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU) - GRID trial
    Reichardt, P.
    Demetri, G.
    Kang, Y-K
    Blay, J-Y
    Joensuu, H.
    Maki, R.
    Rutkowski, P.
    Hohenberger, P.
    Gelderblom, H.
    Leahy, M.
    von Mehren, M.
    Schoffski, P.
    Blackstein, M.
    Le Cesne, A.
    Badalamenti, G.
    Xu, J.
    Nishida, T.
    Laurent, D.
    Kuss, I
    Casali, P.
    ONKOLOGIE, 2012, 35 : 168 - 168
  • [33] Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
    Casali, P. G.
    Reichardt, P.
    Kang, Y.
    Blay, J.
    Joensuu, H.
    Maki, R. G.
    Rutkowski, P.
    Hohenberger, P.
    Gelderblom, H.
    Leahy, M. G.
    von Mehren, M.
    Schoffski, P.
    Blackstein, M. E.
    Le Cesne, A.
    Badalamenti, G.
    Xu, J.
    Nishida, T.
    Laurent, D.
    Kuss, I.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2015, 26 : 29 - 29
  • [34] CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
    Hirano, Hidekazu
    Naito, Yoichi
    Sundar, Raghav
    Komatsu, Yoshito
    Kurokawa, Yukinori
    Li, Jian
    Ozaka, Masato
    Iwatsuki, Masaaki
    Chen, Jen-Shi
    Yen, Chueh-Chuan
    Zalcberg, John Raymond
    Roy, Amitesh Chandra
    Chen, Li-Tzong
    Nishida, Toshirou
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS97 - TPS97
  • [35] Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.
    Kindler, H. L.
    Campbell, N. P.
    Wroblewski, K.
    Maki, R. G.
    D'Adamo, D. R.
    Chow, W. A.
    Gandara, D. R.
    Antonescu, C.
    Stadler, W. M.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT plus gastrointestinal stromal tumors (GIST).
    von Mehren, M.
    Heinrich, M. C.
    Joensuu, H.
    Blanke, C. D.
    Wehrle, E.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.
    Demetri, George D.
    Reichardt, Peter
    Kang, Yoon-Koo
    Blay, Jean-Yves
    Joensuu, Heikki
    Maki, Robert G.
    Rutkowski, Piotr
    Hohenberger, Peter
    Gelderblom, Hans
    Leahy, Michael Gordon
    von Mehren, Margaret
    Schoffski, Patrick
    Blackstein, Martin E.
    Le Cesne, Axel
    Badalamenti, Giuseppe
    Xu, Jian-Ming
    Nishida, Toshirou
    Laurent, Dirk
    Kuss, Iris
    Casali, Paolo Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update
    Blay, J. Y.
    Casali, P. G.
    Reichardt, P.
    von Mehren, M.
    Debiec-Rychter, M.
    Bailey, S.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RADOO1) and Gemcitabine (GEM) in patients (pts) with advanced cancers
    Pacey, S
    Rea, D
    Steven, N
    Brock, C
    Knowlton, N
    Shand, N
    Hazell, K
    Zoellner, U
    O'Donnell, A
    Judson, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 224S - 224S
  • [40] Phase II study of everolimus (E) with imatinib (IM) in patients with previously-treated renal carcinoma (RCC)
    Ryan, C. W.
    Vuky, J.
    Chan, J. S.
    Beer, T. M.
    Rothkopf, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345